Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

838 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis.
Benkert P, Maleska Maceski A, Schaedelin S, Oechtering J, Zadic A, Vilchez Gomez JF, Melie-Garcia L, Cagol A, Galbusera R, Subramaniam S, Lorscheider J, Galli E, Mueller J, Fischer-Barnicol B, Achtnichts L, Findling O, Lalive PH, Bridel C, Uginet M, Müller S, Pot C, Mathias A, Du Pasquier R, Salmen A, Hoepner R, Chan A, Disanto G, Zecca C, D'Souza M, Hemkens LG, Yaldizli Ö, Derfuss T, Roth P, Gobbi C, Brassat D, Tackenberg B, Pedotti R, Raposo C, Oksenberg J, Wiendl H, Berger K, Hermesdorf M, Piehl F, Conen D, Buser A, Kappos L, Khalil M, Granziera C, Abdelhak A, Leppert D, Willemse EAJ, Kuhle J; Swiss MS Cohort study (SMSC). Benkert P, et al. Among authors: d souza m. Ann Neurol. 2024 Oct 16. doi: 10.1002/ana.27096. Online ahead of print. Ann Neurol. 2024. PMID: 39411917
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli Ö, Maceski A, Oechtering J, Achtnichts L, Conen D, Derfuss T, Lalive PH, Mueller C, Müller S, Naegelin Y, Oksenberg JR, Pot C, Salmen A, Willemse E, Kockum I, Blennow K, Zetterberg H, Gobbi C, Kappos L, Wiendl H, Berger K, Sormani MP, Granziera C, Piehl F, Leppert D, Kuhle J; NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group. Benkert P, et al. Lancet Neurol. 2022 Mar;21(3):246-257. doi: 10.1016/S1474-4422(22)00009-6. Lancet Neurol. 2022. PMID: 35182510
Complement Activation Is Associated With Disease Severity in Multiple Sclerosis.
Oechtering J, Stein K, Schaedelin SA, Maceski AM, Orleth A, Meier S, Willemse E, Qureshi F, Heijnen I, Regeniter A, Derfuss T, Benkert P, D'Souza M, Limberg M, Fischer-Barnicol B, Achtnichts L, Mueller S, Salmen A, Lalive PH, Bridel C, Pot C, Du Pasquier RA, Gobbi C, Wiendl H, Granziera C, Kappos L, Trendelenburg M, Leppert D, Lunemann JD, Kuhle J; Swiss MS Cohort Study. Oechtering J, et al. Neurol Neuroimmunol Neuroinflamm. 2024 Mar;11(2):e200212. doi: 10.1212/NXI.0000000000200212. Epub 2024 Feb 14. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38354323 Free article.
Dimethyl fumarate for multiple sclerosis.
Papadopoulou A, D'Souza M, Kappos L, Yaldizli O. Papadopoulou A, et al. Expert Opin Investig Drugs. 2010 Dec;19(12):1603-12. doi: 10.1517/13543784.2010.534778. Epub 2010 Nov 11. Expert Opin Investig Drugs. 2010. PMID: 21067468 Review.
Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis.
Cerdá-Fuertes N, Stoessel M, Mickeliunas G, Pless S, Cagol A, Barakovic M, Maceski AM, Álvarez González C, D' Souza M, Schaedlin S, Benkert P, Calabrese P, Gugleta K, Derfuss T, Sprenger T, Granziera C, Naegelin Y, Kappos L, Kuhle J, Papadopoulou A. Cerdá-Fuertes N, et al. Mult Scler. 2023 Nov;29(13):1540-1550. doi: 10.1177/13524585231198760. Epub 2023 Sep 29. Mult Scler. 2023. PMID: 37772490 Free PMC article.
838 results